BioNTech SE

BNTX

US09075V1026

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:25:34 11/06/2026 pm IST			5-day change	1st Jan Change
88.66 ^USD	+2.92%		-0.96%	-6.80%

08:40pm	European Equities Traded in US as ADRs Rise in Thursday Trading	MT
07:23pm	Commission's appeal against COVID vaccine contract disclosures should be dismissed, court adviser says	RE

BIONTECH : Receives a Buy rating from Berenberg

Published on 05/12/2026 at 12:16 pm IST

MarketScreener with dpa-AFX Analyser

BIONTECH SE

+2.92%

Berenberg is positive on the stock with a Buy rating. The target price is lowered from USD 155 to USD 140.

Latest news about BioNTech SE

08:40pm	European Equities Traded in US as ADRs Rise in Thursday Trading	MT
07:23pm	Commission's appeal against COVID vaccine contract disclosures should be dismissed, court adviser says	RE
09/06	Cancer vaccines based on mRNA advance, despite US cuts	RE
08/06	Wanted: Billions in Venture Capital to Fuel Growth	DP
03/06	BioNTech Says Germany's Health Reforms Could Impact Investment Plans	MT
03/06	Arcus Biosciences Partners With Bristol Myers Squibb to Develop Kidney Cancer Treatment	MT
03/06	Arcus to Supply Experimental Kidney Cancer Drug for Myers Squibb Trial	DJ
01/06	European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading	MT
01/06	BIONTECH : Buy rating from Jefferies	ZD
29/05	Pfizer says EC authorizes update to pediatric use of Pfizer & BioNTech Covid 19 vaccine	RE
29/05	European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Flat for Week	MT
28/05	European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday	MT
28/05	Pfizer, BioNTech prepared to supply 2026-2027 COVID vaccine formula per FDA recommendation and upon approval: briefing docs	RE
27/05	BioNTech's Cancer Pipeline Seen Strengthening Ahead of Key Trial Results, UBS Says	MT
27/05	European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading	MT

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Employees

7,807

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company